MicroFluidic Systems begins Phase III contract to prepare BAND system for manufacturing

May 23, 2007 — /PRNewswire/ — FREMONT, CA — MicroFluidic Systems, a privately held company, announced today that it will begin its Phase III effort of the Bioagent Autonomous Networked Detector (BAND) development contract from the Department of Homeland Security’s (DHS) Science and Technology Directorate.

MFSI was awarded the Phase III program in January of this year and is currently completing its Phase II program. MFSI’s Phase II system was successfully tested by independent personnel and shown to meet the requirements to proceed. MFSI is preparing its BAND system for continued testing and a pilot manufacturing run in fiscal year 2008. Phase III will be the final stage of development of the BAND system, which will be deployed as part of the nation’s BioWatch program.

Coupled with its on-going contract with DHS Science and Technology for the development of an instantaneous bioaerosol detection system (IBADS) and its stand-alone laboratory sample processing instruments, MFSI continues to offer a variety of solutions for automated biological agent detection. Practical applications for these technologies go beyond homeland security and biodefense to areas such as clinical diagnostics, emerging disease monitoring, industrial testing, forensics, and research.

“We are excited about being one of the few entities selected to continue this important work for DHS,” commented Dr. M. Allen Northrup, MFSI president and CEO. “This continuation of the BAND program represents a huge business and growth opportunity for MFSI,” he added.

MicroFluidic Systems (MFSI) was founded in 2001 and is focused on the development of microfluidic systems for automated preparation of biological assays. MFSI personnel have been involved with the development of automated DNA-based pathogen detection systems and microfluidics for the US Government and commercial markets for over 12 years, including the world’s first miniaturized, portable, battery-operated, real-time, polymerase-chain-reaction (PCR)-based detection system. For more information, please contact MFSI at 510-354-0400 or visit the website, http://www.microfluidicsystems.com/.

Source: MicroFluidic Systems

MFSI, +1-510-354-0400, ext. 201


Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.